Atypical  	Atypical  	 FW	B-NP
hemolytic  	hemolytic  	 FW	I-NP
uremic  	uremic  	 FW	I-NP
syndrome  	syndrome  	 FW	I-NP
( 	( 	 -LRB-	O
aHUS 	aHUS 	 NNP	B-NP
) 	) 	 -RRB-	O
:  	:  	 :	O
making  	making  	 VBG	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 FW	O
Atypical  	Atypical  	 FW	B-NP
hemolytic  	hemolytic  	 FW	I-NP
uremic  	uremic  	 FW	I-NP
syndrome  	syndrome  	 FW	I-NP
( 	( 	 -LRB-	O
aHUS 	aHUS 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
major  	major  	 JJ	O
thrombotic  	thrombotic  	 JJ	B-NP
microangiopathy  	microangiopathy  	 NNS	I-NP
( 	( 	 -LRB-	O
TMA 	TMA 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
TMA  	TMA  	 NNP	B-NP
is  	is  	 VBZ	O
recognized  	recognized  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
laboratory  	laboratory  	 NN	B-NP
signs  	signs  	 NNS	I-NP
of  	of  	 IN	I-NP
microangiopathic  	microangiopathic  	 JJ	I-NP
hemolysis 	hemolysis 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
indicated  	indicated  	 VBN	O
by  	by  	 IN	O
schistocytes 	schistocytes 	 NN	B-NP
,  	,  	 ,	O
elevated  	elevated  	 VBD	O
lactate  	lactate  	 JJ	B-NP
dehydrogenase 	dehydrogenase 	 NN	I-NP
,  	,  	 ,	O
low  	low  	 JJ	O
haptoglobin 	haptoglobin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
low  	low  	 JJ	O
hemoglobin 	hemoglobin 	 NN	B-NP
,  	,  	 ,	O
plus  	plus  	 CC	O
thrombocytopenia  	thrombocytopenia  	 NNS	B-NP
and  	and  	 CC	O
accompanying  	accompanying  	 JJ	O
signs  	signs  	 NNS	O
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	I-NP
organ  	organ  	 JJ	I-NP
system  	system  	 NN	I-NP
involvement.  	involvement.  	 CD	I-NP
aHUS  	aHUS  	 JJ	O
results  	results  	 NNS	O
from  	from  	 IN	O
chronic 	chronic 	 NN	O
,  	,  	 ,	O
uncontrolled  	uncontrolled  	 JJ	O
activity  	activity  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
alternative  	alternative  	 JJ	O
complement  	complement  	 JJ	B-NP
pathway 	pathway 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
most  	most  	 JJS	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
this  	this  	 DT	O
defect  	defect  	 NN	O
is  	is  	 VBZ	O
related  	related  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
genetic  	genetic  	 JJ	B-NP
deficiency  	deficiency  	 NN	I-NP
in  	in  	 IN	O
one  	one  	 CD	O
or  	or  	 CC	O
more  	more  	 RBR	O
soluble  	soluble  	 JJ	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
membrane-bound  	membrane-bound  	 JJ	B-NP
complement  	complement  	 JJ	I-NP
regulatory  	regulatory  	 JJ	I-NP
proteins 	proteins 	 NNS	I-NP
.  	.  	 .	O
Complement  	Complement  	 JJ	B-NP
factor  	factor  	 NN	I-NP
H  	H  	 NNP	I-NP
is  	is  	 VBZ	O
most  	most  	 RBS	O
frequently  	frequently  	 RB	O
implicated 	implicated 	 VBN	O
.  	.  	 .	O
Clinically 	Clinically 	 NNP	O
,  	,  	 ,	O
aHUS  	aHUS  	 NNP	B-NP
is  	is  	 VBZ	O
often  	often  	 RB	O
indistinguishable  	indistinguishable  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
TMAs 	TMAs 	 NN	B-NP
:  	:  	 :	O
Shiga  	Shiga  	 NNP	B-NP
toxin–producing  	toxin–producing  	 NNP	I-NP
Escherichia  	Escherichia  	 NNP	I-NP
coli  	coli  	 NNS	I-NP
( 	( 	 -LRB-	O
STEC 	STEC 	 NNP	B-NP
)  	)  	 -RRB-	O
hemolytic  	hemolytic  	 JJ	B-NP
uremic  	uremic  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
and  	and  	 CC	O
thrombotic  	thrombotic  	 FW	B-NP
thrombocytopenic  	thrombocytopenic  	 FW	I-NP
purpura  	purpura  	 FW	I-NP
( 	( 	 -LRB-	O
TTP 	TTP 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
TTP  	TTP  	 NNP	B-NP
and  	and  	 CC	O
aHUS  	aHUS  	 NNS	B-NP
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
high  	high  	 JJ	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality.  	mortality.  	 NNP	O
aHUS  	aHUS  	 NNP	B-NP
has  	has  	 VBZ	O
a  	a  	 DT	O
distinct  	distinct  	 JJ	O
pathology  	pathology  	 NN	B-NP
from  	from  	 IN	O
TTP 	TTP 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
nearly  	nearly  	 RB	O
all  	all  	 DT	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
aHUS  	aHUS  	 NNP	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
distinguished  	distinguished  	 VBN	O
from  	from  	 IN	O
TTP  	TTP  	 NNP	B-NP
on  	on  	 IN	O
the  	the  	 DT	O
basis  	basis  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
ADAMTS13  	ADAMTS13  	 NNP	B-NP
( 	( 	 -LRB-	O
a  	a  	 DT	O
disintegrin  	disintegrin  	 NN	B-NP
and  	and  	 CC	O
metalloproteinase  	metalloproteinase  	 NN	B-NP
with  	with  	 IN	O
a  	a  	 DT	O
thrombospondin  	thrombospondin  	 JJ	B-NP
type  	type  	 NN	I-NP
1  	1  	 CD	O
motif 	motif 	 NN	B-NP
,  	,  	 ,	O
member  	member  	 NN	O
13 	13 	 CD	O
)  	)  	 -RRB-	O
enzyme  	enzyme  	 JJ	B-NP
activity  	activity  	 NN	I-NP
measurement 	measurement 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
essential  	essential  	 JJ	O
that  	that  	 IN	O
aHUS  	aHUS  	 JJ	O
and  	and  	 CC	O
TTP  	TTP  	 NNP	B-NP
be  	be  	 VB	O
differentiated  	differentiated  	 VBN	O
quickly 	quickly 	 RB	O
,  	,  	 ,	O
as  	as  	 IN	O
they  	they  	 PRP	O
require  	require  	 VBP	O
markedly  	markedly  	 RB	O
divergent  	divergent  	 JJ	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
standard  	standard  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
TTP  	TTP  	 NNP	B-NP
is  	is  	 VBZ	O
plasma  	plasma  	 JJ	B-NP
exchange 	exchange 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
therapy  	therapy  	 NN	O
that  	that  	 WDT	O
has  	has  	 VBZ	O
no  	no  	 DT	O
role  	role  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
aHUS  	aHUS  	 JJ	O
established  	established  	 VBN	O
by  	by  	 IN	O
ADAMTS13  	ADAMTS13  	 CD	B-NP
activity  	activity  	 NN	I-NP
levels 	levels 	 NNS	I-NP
.  	.  	 .	O
